Alcohol and Alcoholism Advance Access originally published online on March 22, 2006
Alcohol and Alcoholism 2006 41(3):231-235; doi:10.1093/alcalc/agl013
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROSIGLITAZONE RELIEVES ACUTE ETHANOL-INDUCED HANGOVER IN SPRAGUE–DAWLEY RATS
1 The Brain Korea 21 Project for Medical Science, 2 Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea and 3 Department of Internal Medicine, Pochon CHA University College of Medicine, Sungnam, Korea
* Author to whom correspondence should be addressed at: Department of Internal Medicine, School of Medicine, Yonsei University, 134 Shinchon-Dong, Seodaemoon-Ku, P.O. Box 120-749, Seoul, Korea. Tel.: +822 2228 1962; Fax: +822 393 6884; E-mail: bscha{at}yumc.yonsei.ac.kr
(Received 24 October 2005; first review notified 22 December 2005; in revised form 2 February 2006; accepted 3 February 2006)
Aims: To assess the efficacy of rosiglitazone in blocking ethanol-induced hangover in rats. Methods: Rats injected with ethanol (4 g/kg body weight) were subjected to social interaction tests. Levels of aldehyde dehydrogenase 2 (ALD2), involved in an anti-hangover mechanism, were measured by semi-quantitative RT–PCR and western blot analysis. Results: Rosiglitazone caused an upregulation of mitochondrial ALD2, thus significantly detoxifying acetaldehyde. Conclusions: Rosiglitazone alleviated the symptoms of ethanol-induced hangover by inducing ALD2 expression; this result was reconfirmed by eliminating the effect of rosiglitazone by injecting cyanamide, an ALD2 inhibitor.